Moderna to Present Key 5-Year Cancer Data at ASCO; Q1 Revenue Up 260%
MRNA has more than doubled off its 52-week low of $22.28 on elevated volume (2.6× avg).
Summary
Moderna announced it will present significant oncology data at the upcoming ASCO 2026 conference in late May, including five-year follow-up results for its mRNA-4157/V940 combination therapy with Keytruda, along with updates from renal cell carcinoma and melanoma trials. This is a crucial future catalyst for the company's pipeline beyond its established vaccine business. The company also reported Q1 2026 revenue of $389 million, a 260% year-over-year increase that exceeded expectations, though the core Q1 results were previously announced on May 1st. Separately, Evercore ISI issued a warning that Moderna's hantavirus vaccine partnership is not expected to be a near-term revenue driver. Traders will closely monitor the ASCO presentations for potential advancements in Moderna's oncology pipeline.
At the time of this announcement, MRNA was trading at $54.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.6B. The 52-week trading range was $22.28 to $59.55. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.